Cargando…

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer

MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Watahiki, Akira, Macfarlane, Robyn J., Gleave, Martin E., Crea, Francesco, Wang, Yuzhuo, Helgason, Cheryl D., Chi, Kim N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645714/
https://www.ncbi.nlm.nih.gov/pubmed/23574937
http://dx.doi.org/10.3390/ijms14047757
_version_ 1782268529364434944
author Watahiki, Akira
Macfarlane, Robyn J.
Gleave, Martin E.
Crea, Francesco
Wang, Yuzhuo
Helgason, Cheryl D.
Chi, Kim N.
author_facet Watahiki, Akira
Macfarlane, Robyn J.
Gleave, Martin E.
Crea, Francesco
Wang, Yuzhuo
Helgason, Cheryl D.
Chi, Kim N.
author_sort Watahiki, Akira
collection PubMed
description MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.
format Online
Article
Text
id pubmed-3645714
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-36457142013-05-13 Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer Watahiki, Akira Macfarlane, Robyn J. Gleave, Martin E. Crea, Francesco Wang, Yuzhuo Helgason, Cheryl D. Chi, Kim N. Int J Mol Sci Article MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC. Molecular Diversity Preservation International (MDPI) 2013-04-10 /pmc/articles/PMC3645714/ /pubmed/23574937 http://dx.doi.org/10.3390/ijms14047757 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Watahiki, Akira
Macfarlane, Robyn J.
Gleave, Martin E.
Crea, Francesco
Wang, Yuzhuo
Helgason, Cheryl D.
Chi, Kim N.
Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title_full Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title_fullStr Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title_full_unstemmed Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title_short Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
title_sort plasma mirnas as biomarkers to identify patients with castration-resistant metastatic prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645714/
https://www.ncbi.nlm.nih.gov/pubmed/23574937
http://dx.doi.org/10.3390/ijms14047757
work_keys_str_mv AT watahikiakira plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT macfarlanerobynj plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT gleavemartine plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT creafrancesco plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT wangyuzhuo plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT helgasoncheryld plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer
AT chikimn plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer